A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
- Guangyu Zhao†1,
- Lanying Du†2,
- Cuiqing Ma2,
- Ye Li2,
- Lin Li1,
- Vincent KM Poon3,
- Lili Wang2,
- Fei Yu2,
- Bo-Jian Zheng3,
- Shibo Jiang2, 4Email author and
- Yusen Zhou1Email author
© Zhao et al.; licensee BioMed Central Ltd. 2013
Received: 24 April 2013
Accepted: 23 August 2013
Published: 26 August 2013
Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors.
In this study, we produced a pseudovirus bearing the full-length spike (S) protein of MERS-CoV in the Env-defective, luciferase-expressing HIV-1 backbone. We then established a pseudovirus-based inhibition assay to detect neutralizing antibodies and anti-MERS-CoV entry inhibitors.
Our results demonstrated that the generated MERS-CoV pseudovirus allows for single-cycle infection of a variety of cells expressing dipeptidyl peptidase-4 (DPP4), the confirmed receptor for MERS-CoV. Consistent with the results from a live MERS-CoV-based inhibition assay, the antisera of mice vaccinated with a recombinant protein containing receptor-binding domain (RBD, residues 377–662) of MERS-CoV S fused with Fc of human IgG exhibited neutralizing antibody response against infection of MERS-CoV pseudovirus. Furthermore, one small molecule HIV entry inhibitor targeting gp41 (ADS-J1) and the 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) could significantly inhibit MERS-CoV pseudovirus infection.
Taken together, the established MERS-CoV inhibition assay is a safe and convenient pseudovirus-based alternative to BSL-3 live-virus restrictions and can be used to rapidly screen MERS-CoV entry inhibitors, as well as evaluate vaccine-induced neutralizing antibodies against the highly pathogenic MERS-CoV.
KeywordsNovel human coronavirus MERS-CoV Spike protein Pseudovirus Neutralizing antibodies Antiviral therapeutics
In April, 2012, a severe acute respiratory syndrome (SARS)-like disease emerged in Saudi Arabia [1–3]. As of August 13, 2013, the World Health Organization (WHO) had received reports of 94 cases of infection caused by this novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV, previous name hCoV-EMC), including 47 deaths, from several countries, including Saudi Arabia, Qatar, Jordan, the United Arab Emirates, the United Kingdom, France, Germany, Italy, and Tunisia (http://www.who.int/csr/disease/coronavirus_infections/update_20130813/en/). Eight MERS-CoV clusters have been reported, suggesting person-to-person transmission of the disease . However, the transmissibility of MERS-CoV appears to be less efficient than that of SARS-coronavirus (SARS-CoV), the first new infectious disease identified in the 21st century with an approximate mortality rate of 10% .
Genetically, MERS-CoV is closely related to SARS-CoV [1, 6]. Clinically, severe respiratory illness with renal failure caused by MERS-CoV infection is very similar to the symptomology related to SARS . Therefore, the outbreak of MERS-CoV infection has raised serious concerns of a potential global pandemic on the order of SARS in 2003. Accordingly, pursuant to the development of effective vaccines and antiviral agents, the first step requires identification of the neutralizing and inhibitory activities of such anti-MERS-CoV vaccines and therapeutics.
It is now well known that SARS-CoV gains cellular entry through its receptor, angiotensin converting enzyme 2 (ACE2) , whereas MERS-CoV utilizes dipeptidyl peptidase-4 (DPP4, also known as CD26) as its entry receptor . Similar to SARS-CoV, the spike (S) protein of MERS-CoV also plays important roles in receptor binding and viral entry [5, 9]. As the major protein causing virus infection, S protein is an ideal target for both vaccines and MERS-CoV entry inhibitors.
In this study, we produced a pseudovirus bearing the full-length S protein of MERS-CoV in the Env-defective, luciferase-expressing HIV-1 backbone. We then established a pseudovirus-based inhibition assay for the detection of neutralizing antibodies and anti-MERS-CoV entry inhibitors. This method was proven to be safe, convenient, reliable and effective for the rapid detection of neutralizing antibodies and viral entry inhibitors against MERS-CoV.
Generated MERS-CoV pseudovirus was able to infect a variety of cell types from human and non-human hosts
Cell lines used for detection of MERS-CoV pseudovirus infectivity and receptor DPP4 expression
Dr. Charles M. Rice at Rockefeller University
NIH AIDS Reagent Program
Human respiratory tract
Human intestinal tract
Human genitourinary tract
Express SARS-CoV receptor ACE2
Fetal rhesus monkey kidney
African green monkey kidney
African green monkey kidney
African green monkey kidney
MERS-CoV pseudovirus inhibition assay reliably detected the neutralizing activity of vaccinated animal sera, and the result was consistent with that of live MERS-CoV-based inhibition assay
MERS-CoV pseudovirus inhibition assay could be used to effectively screen for MERS-CoV entry inhibitors
We then detected the potential cytotoxicity of the identified compounds to Huh-7 cells that were used for testing their inhibitory activity on MERS-CoV pseudovirus. As shown in Figure 4C, HP-HSA had no significant cytotoxicity at the concentration as high as 100 μM. ADS-J1 exhibited some cytotoxicity to Huh-7 cells with CC50 (the concentration causing 50% cytotoxicity) of 26.9 μM. However, its IC50 (the concentration causing 50% inhibition of MERS-CoV pseudovirus infection) is 0.6 μM and its selective index (CC50/IC50) is about 45. These data indicated that the decreased infectivity of the peudotyped MERS-CoV in the presence of these compounds is not due to their cytotoxicity, but is associated with their inhibition on MERS-CoV entry. These results confirmed that the established pseudovirus inhibition assay could be used as an effective way to rapidly screen MERS-CoV entry inhibitors.
Angiotensin-converting enzyme 2 (ACE2) has been confirmed as the receptor of SARS-CoV , while MERS-CoV has been shown to bind target cells using DPP4 as its receptor . In this study, we generated a pseudotyped MERS-CoV based on the viral surface S protein, and detected its infectivity in different cell types. Indeed, the generated pseudovirus was able to infect a variety of cell lines, including human and non-human cell types. Generally, its cell susceptibility was consistent with that of wildtype MERS-CoV reported previously , being able to maintain high infectivity in DPP4-expressing cells, such as Huh-7, MDCK, Vero, Vero E6, FRhK4, HEP-G2, and A549, and incapable of infecting HeLa and MA-104 cells with no DPP4 expression. Its infectivity to DPP4-expressing PK-15 and Caco-2 cells was relatively lower than that of wildtype virus . This is possibly because that pseudotyped MERS-CoV, which contains only viral S protein with ability of single-cycle infection but lacks the capability for multiple rounds of replication, might have lower infectivity than wildtype MERS-CoV that contains all viral proteins necessary for virus replication.
It is noted that MERS-CoV pseudovirus had a relatively higher infectivity in HT-1080, Hep-2, MT-2 and NBL-7 cells with undetectable DPP4 expression, suggesting that the infectivity of MERS-CoV pseudovirus might not be completely associated with the expression level of DPP4. Similar phenomena were observed by Pohlmann and the colleagues, showing that the lentiviral pseudotype had a lower infectivity in DPP4-expressing A549 and that 293T cells from different batches maintained variant infectivities . Reports have shown that HEK cells with undetectable DPP4 had relatively higher infectivity to wildtype MERS-CoV . It may be possible that like SARS-CoV, which has alternative receptors (such as DC-SIGN and/or L-SIGN) in addition to ACE2 [5, 19, 20], MERS-CoV might also have an alternative receptor that has not been identified so far.
Notably, the peptides derived from the HIV-1 gp41 HR2 region, C34 and T20, had a moderate inhibitory activity on MERS-CoV entry into NBL-7 cells, but exhibited no inhibition on MERS-CoV entry into Huh-7 cells. These results suggest that C34 and T20 peptides may interact with the HR1 conformation of MERS-CoV S protein S2 subunit induced by the binding of S1 subunit to the not-yet-identified alternative receptor on NBL-7 cells. However, these peptides may not be able to interact with the HR1 conformation of MERS-CoV S protein S2 subunit induced by the binding of S1 subunit to the well-defined receptor DPP4 on Huh-7 cells.
Live virus-based inhibition assays have generally been used to detect neutralizing antibodies against infection of SARS-CoV or other coronaviruses [21, 22]. However, to carry out this type of inhibition assay, it is necessary to utilize biosafety level 3 (BSL-3) facilities. Unfortunately, this strict condition is often inconvenient and cannot be accessed by many researchers. In contrast, our pseudovirus-based inhibition assay can be performed without the requirement of BSL-3 laboratories, considerably simplifying the detection of neutralizing antibodies, as this method does not involve live viruses and is, therefore, safe to carry out [10, 23]. Moreover, we demonstrated consistency of neutralization results between the live virus-based inhibition assay and the established pseudovirus-based inhibition assay. These neutralizing results are also consistent with those obtained from the experiments on antisera of mice immunized by another RBD fragment containing residues 358–588 of MERS-CoV S protein, as reported recently . The above results suggest a viable alternative for the rapid detection of neutralizing antibodies against MERS-CoV natural infection and the preclinical evaluation of candidate vaccines when BSL-3 facilities are not available. Furthermore, in the absence of BSL-3 facilities, the pseudovirus-based inhibition assay provides a convenient and reliable way to rapidly screen compound- or peptide-based MERS-CoV entry inhibitors to test neutralizing antibodies. With easy production of pseudovirus, rapid read-out and detection of inhibition, this method is particularly suitable for handling a large variety of samples in a short period of time.
Our study showed that the established MERS-CoV inhibition assay is a safe and convenient pseudovirus-based alternative to BSL-3 live-virus restrictions and can be used to rapidly screen MERS-CoV entry inhibitors, as well as evaluate vaccine-induced neutralizing antibodies against the highly pathogenic MERS-CoV.
The study of animals was approved by the Institutional Animal Care and Use Committee at the New York Blood Center (Approval #194.14). All animal studies were carried out in strict accordance with the recommendations of the American Veterinary Medical Association (AVMA) Guidelines and the approved protocols.
Huh-7, HEP-G2, HT-1080, MT-2, Hep-2, Caco-2, HeLa, 293T, ACE2/293T, A549, NBL-7, PK15, MDCK, FRhK-4, Vero, Vero E6, and MA-104 cells were used for detection of pseudovirus infectivity and for identification of expression of MERS-CoV’s receptor DPP4. Information on these cell lines as well as their origins and providers was specifically described in Table 1.
Recombinant plasmid construction
The codon-optimized genes expressing full-length S protein of MERS-CoV (humanbetacoronavirus 2c EMC/2012, hCoV-EMC, GenBank accession no. AFS88936.1) were synthesized by GenScript (Nanjing, China) by replacement of the N-terminal signal peptide (residues 1–17) with CD5 signal sequence and insertion into pcDNA3.1 vector (Invitrogen, Carlsbad, CA). The constructed recombinant MERS-CoV plasmid (rMERS-CoV-S) containing the S gene was confirmed for correct insertion by sequencing analysis.
Production of MERS-CoV pseudovirus bearing S protein
Generation of MERS-CoV pseudovirus was done as previously described with some modifications . Briefly, 293T cells (ATCC, Manassas, VA) were co-transfected with 20 μg of plasmid encoding Env-defective, luciferase-expressing HIV-1 (pNL4-3.luc.RE) and 20 μg of rMERS-CoV-S plasmid, respectively, into a-T175 tissue culture flask using the calcium phosphate method. Cells were changed into fresh DMEM 8 h later. Supernatants were harvested 72 h post-transfection and used for single-cycle infection. The plasmids encoding vesicular stomatitis virus G protein (VSV-G-pcDNA3.1) and pcDNA3.1 vector were co-transfected with pNL4-3.luc.RE plasmid to generate VSV-G pseudovirus and pseudovirus without Env (Env-) as controls.
The p24 content in the produced MERS-CoV pseudovirus was quantified by ELISA, as previously described, with some modifications . Briefly, ELISA plates were precoated with HIVIG (5 μg/ml) overnight at 4°C and blocked at 37°C for 2 h. Lysed pseudovirus was added to the plates and incubated at 37°C for 1 h. After washes, the plates were respectively incubated with anti-p24 mAb (183-H12-5C, 1:20) and then with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG at 37°C for 1 h. The substrate 3,30,5,50-tetramethylbenzidine (TMB) (Zymed, Carlsbad, CA) was added, and the reaction was stopped by 1 N H2SO4. The absorbance at 450 nm (A450) was measured by ELISA Plate Reader (Tecan, San Jose, CA).
Detection of MERS-CoV pseudovirus infectivity
To detect infectivity, different target cells (104/well in 96-well plates) from various sources (Table 1) were respectively infected with MERS-CoV pseudovirus. Fresh DMEM was added 12 h post-infection, and RLU was measured 72 h later by Ultra 384 luminometer (Tecan).
Western blot was performed to detect HIV-1 p24 and MERS-CoV S protein in the generated pseudovirus, and to identify expression of DPP4 in cells susceptible to MERS-CoV pseudovirus as previously described with some modifications . Briefly, lysed pseudovirus (200 ng/ml p24) or cell lysates (30 μg total proteins) were respectively separated by 10% Tris-glycine gels, which were then transferred to nitrocellulose membranes. After blocking with 5% non-fat milk in PBST overnight at 4°C, the blots were respectively incubated with anti-p24 (183-H12-5C, 1:50), anti-S of MERS-CoV (1:200) (prepared in our laboratory), and goat anti-DPP4 (1 μg/ml, R&D Systems, Minneapolis, MN), for 1 h at room temperature. After three washes, the blots were then incubated with HRP-conjugated anti-mouse IgG (for HIV-1 p24 and MERS-CoV S, 1:3,000, Invitrogen) or anti-goat IgG (for DPP4, 1 1:3,000, R&D Systems) for 1 h at room temperature. Signals were visualized with ECL Western blot substrate reagents and Amersham Hyperfilm (GE Healthcare).
Expression and purification of recombinant protein
The construction, expression and purification of the recombinant protein fused with Fc (S-RBD-Fc) were done as previously described [11, 25]. Briefly, genes encoding RBD (residues 377–662) of MERS-CoV S protein were amplified by PCR using synthesized codon-optimized full-length S sequences of MERS-CoV as the template, which were then digested by EcoR I and Bgl II restriction enzymes and inserted into the pFUSE-hIgG1-Fc2 expression vector (hereinafter named Fc, InvivoGen, San Diego, CA). The sequence-confirmed recombinant plasmid was transfected into 293T cells (ATCC, Manassas, VA) seeded 24 h before transfection, followed by replacement of culture medium by serum-free DMEM (Invitrogen, Carlsbad, CA) 10 h later and then collection of supernatant containing expressed protein 72 h post-transfection. The recombinant protein was purified by Protein A affinity chromatography (GE Healthcare, Piscataway, NJ), according to the manufacturer’s instructions.
Mouse vaccination and serum collection
Mice were subcutaneously immunized with 10 μg/mouse of recombinant MERS-CoV S-RBD-Fc protein formulated with Freund’s complete adjuvant (Sigma, St. Louis, MO) and boosted once with 5 μg/mouse of the immunogen and Freund’s incomplete adjuvant at 2-week intervals. Sera collected at 10 days post-2nd vaccination were used to detect neutralizing activity.
MERS-CoV pseudovirus inhibition assay
Pseudovirus inhibition assay was established to detect neutralizing activity of vaccinated mouse sera and inhibitory ability of antiviral agents against infection of MERS-CoV pseudovirus in target cells . Briefly, pseudovirus-containing supernatants were respectively incubated with serially diluted mouse sera or synthetic compounds at 37°C for 1 h before adding to target cells preplated in 96-well culture plates (104 cells/well). Twenty-four hours later, cells were refed with fresh medium, which was followed by lysing cells 72 h later using cell lysis buffer (Promega) and transferring the lysates into 96-well luminometer plates. Luciferase substrate (Promega) was added to the plates, and relative luciferase activity was determined. The inhibition of MERS-CoV pseudovirus was presented as % inhibition.
MERS-CoV inhibition assay
Neutralizing antibody titers of mouse sera against infection by MERS-CoV live virus were further detected as previously described for SARS-CoV with some modifications [26, 27]. Briefly, serial dilutions of mouse sera were incubated with 100 50% tissue culture infective doses (TCID50) of virus for 1 h at 37°C prior to addition to the monolayer of Vero E6 cells in triplicate. Virus supernatant was removed and replaced with fresh medium after 1 h of culture at 37°C. Cytopathic effect (CPE) in each well was observed daily and recorded on day 3 post-infection. The neutralizing titers of mouse antisera that completely prevented CPE in 50% of the wells (NT50) were calculated as before [26–28].
The in vitro cytotoxicity of the synthetic compounds to Huh-7 target cells was measured by the XTT assay as previously described with some modifications . Briefly, 100 μl of serially diluted compounds in non-color 1640 medium were added to equal volumes of cells (5 × 105/ml) in 96-well tissue culture plates. After incubation at 37°C for 3 days, 50 μl of XTT solution (1 mg/ml) containing 0.02 μM of phenazinemethosulphate (PMS) were added. Four hour later, the absorbance at 450 nm (A 450) was measured with ELISA Plate Reader.
This study was supported in part by the National Program of Infectious Diseases (2012ZX10004-502) and an intramural fund of the New York Blood Center (NYB000068). We thank Dr. Charles M. Rice at The Rockefeller University for his generous gift of the Huh-7 cell line.
- Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY: Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 2012, 65: 477-489. 10.1016/j.jinf.2012.10.002PubMedView ArticleGoogle Scholar
- Zaki AM, Van BS, Bestebroer TM, Osterhaus AD, Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367: 1814-1820. 10.1056/NEJMoa1211721PubMedView ArticleGoogle Scholar
- Pollack MP, Pringle C, Madoff LC, Memish ZA: Latest outbreak news from ProMED-mail: Novel coronavirus - Middle East. Int J Infect Dis 2013, 17: e143-e144. 10.1016/j.ijid.2012.12.001PubMedView ArticleGoogle Scholar
- Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM: Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013, 368: 2487-2494. 10.1056/NEJMoa1303729PubMedView ArticleGoogle Scholar
- Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S: The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol 2009, 7: 226-236. 10.1038/nrmicro2090PubMedPubMed CentralView ArticleGoogle Scholar
- Van BS, De GM, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA: Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3: e00473-e00412.Google Scholar
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426: 450-454. 10.1038/nature02145PubMedView ArticleGoogle Scholar
- Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL: Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495: 251-254. 10.1038/nature12005PubMedView ArticleGoogle Scholar
- Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, Von HT, Simmons G, Hofmann H, Pohlmann S: The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013, 87: 5502-5511. 10.1128/JVI.00128-13PubMedPubMed CentralView ArticleGoogle Scholar
- Du L, Zhao G, Zhang X, Liu Z, Yu H, Zheng BJ, Zhou Y, Jiang S: Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem Biophys Res Commun 2010, 397: 580-585. 10.1016/j.bbrc.2010.05.161PubMedView ArticleGoogle Scholar
- Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S: Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013, 87: 9939-9942. 10.1128/JVI.01048-13PubMedPubMed CentralView ArticleGoogle Scholar
- Debnath AK, Radigan L, Jiang S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999, 42: 3203-3209. 10.1021/jm990154tPubMedView ArticleGoogle Scholar
- Wang H, Qi Z, Guo A, Mao Q, Lu H, An X, Xia C, Li X, Debnath AK, Wu S, Liu S, Jiang S: ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother 2009, 53: 4987-4998. 10.1128/AAC.00670-09PubMedPubMed CentralView ArticleGoogle Scholar
- Li L, Qiu J, Lu L, An S, Qiao P, Jiang S, Liu S: 3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. J Antimicrob Chemother 2013, 68: 573-576. 10.1093/jac/dks458PubMedView ArticleGoogle Scholar
- Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S: HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 2007, 282: 9612-9620. 10.1074/jbc.M609148200PubMedView ArticleGoogle Scholar
- Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM: Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors. J Cell Biochem 2008, 104: 2335-2347. 10.1002/jcb.21790PubMedView ArticleGoogle Scholar
- Lu L, Yang X, Li Y, Jiang S: Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. Microbes Infect 2013, 15: 506-510. 10.1016/j.micinf.2013.03.003PubMedView ArticleGoogle Scholar
- Fuk-Woo CJ, Chan KH, Choi GK, To KK, Tse H, Cai JP, Yeung ML, Cheng VC, Chen H, Che XY, Lau SK, Woo PC, Yuen KY: Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013, 207: 1743-1752. 10.1093/infdis/jit123View ArticleGoogle Scholar
- Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD Jr, Thackray LB, Young MD, Mason RJ, Ambrosino DM, Wentworth DE, Demartini JC, Holmes KV: CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2004, 101: 15748-15753. 10.1073/pnas.0403812101PubMedPubMed CentralView ArticleGoogle Scholar
- Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ: pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004, 78: 5642-5650. 10.1128/JVI.78.11.5642-5650.2004PubMedPubMed CentralView ArticleGoogle Scholar
- Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ: A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005, 86: 1435-1440. 10.1099/vir.0.80844-0PubMedPubMed CentralView ArticleGoogle Scholar
- Pang H, Liu Y, Han X, Xu Y, Jiang F, Wu D, Kong X, Bartlam M, Rao Z: Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004, 85: 3109-3113. 10.1099/vir.0.80111-0PubMedView ArticleGoogle Scholar
- Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA: Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 2005, 11: 411-416. 10.3201/eid1103.040906PubMedPubMed CentralView ArticleGoogle Scholar
- Mou H, Raj VS, Van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ: The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013, 87: 9379-9383. 10.1128/JVI.01277-13PubMedPubMed CentralView ArticleGoogle Scholar
- Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S: A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 2013, 8: e53568. 10.1371/journal.pone.0053568PubMedPubMed CentralView ArticleGoogle Scholar
- Du L, Zhao G, Li L, He Y, Zhou Y, Zheng BJ, Jiang S: Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun 2009, 384: 486-490. 10.1016/j.bbrc.2009.05.003PubMedPubMed CentralView ArticleGoogle Scholar
- Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng BJ: Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008, 180: 948-956.PubMedPubMed CentralView ArticleGoogle Scholar
- Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S: Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009, 393: 144-150. 10.1016/j.virol.2009.07.018PubMedPubMed CentralView ArticleGoogle Scholar
- Li L, Qiao P, Yang J, Lu L, Tan S, Lu H, Zhang X, Chen X, Wu S, Jiang S, Liu S: Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology 2010, 7: 37. 10.1186/1742-4690-7-37PubMedPubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.